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Cell therapies offer exciting, novel strategies for treating acute, chronic, and incurable diseases. This 
technology represents a “eureka moment,” according to the former FDA head, Scott Gottlieb. This field 
has undergone several generations of development, from stem cell transplantation, to dendritic cell 
modification, and developing most recently into autologous CAR-T therapies that have been highly 
effective against some blood cancers. However, these recent autologous therapies have been limited by 
daunting costs, highly variable process outcomes, a lack of reliable assays, and supply chains that are 
both immature and risky. Call this Cell Therapy 1.0. Allogeneic therapies, either from primary donors or 
induced pluripotent lines, or Cell Therapy 2.0, are being currently developed. As these are nucleated cells 
with the potential for significant expansion in vivo, they still carry substantial safety concerns. Rubius 
Therapeutics is leapfrogging the allogeneic adoptive transfer approaches by developing Red Cell 
Therapeutics™, in which therapeutic proteins are expressed in or on genetically engineered, enucleated 
red blood cells. This versatile, innovative 3.0 platform enables us to efficiently target immune-oncology, 
inborn metabolic disorders, and autoimmune indications. It also makes cell therapy more akin to a routine 
monoclonal antibody business model with greater scale, flexibility, reliability, and cost competitiveness 
relative to current autologous and allogeneic technologies. However, the traditional process metrics used 
in manufacturing monoclonal antibodies must be adjusted to account for the unique considerations of red 
cell manufacture. Rubius monitors a variety of phenotypical and product-specific biomarkers that track the 
progression of cells through erythroid differentiation in conjunction with seed train steps in the process. 
Methods to understand which attributes are predictive of process outcome and final product quality are at 
the forefront of Rubius’ analytical strategy. By understanding allogeneic cell manufacturing – specific 
process development challenges and developing analytical methods capable of reliably predicting 
process performance and product quality, Rubius expects to develop the next generation of cellular 
therapies that are cost effective, consistent, and efficacious against incurable diseases. 
